Dofequidar, an ABC transporter inhibitor, increases the chemosensitivity of bCSCs in advanced or recurrent BC patients, when administered in combination with chemo drugs like doxorubicin, fluorouracil, and cyclophosphamide (109). This evidence concerns the gene ABCG2 and breast cancer.